Dr. Atish Choudhury
Senior Physician, Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School
Dr. Atish Choudhury is a clinical and translational investigator in the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and is Chair of the Gelb Center for Translational Research. He previously served as co-director of the Prostate Cancer Center at Dana-Farber/Brigham and Women's Cancer Center.
Dr. Choudhury has received a Young Investigator Award and PCF/Pfizer Global Challenge Award from the Prostate Cancer Foundation, and a Physician Scientist Training Award and Translational Science Award from the Department of Defense. His primary research interests are in development of novel therapeutic strategies and biomarkers in advanced prostate cancers.
Dr. Jordan Ciuro
Assistant Professor of Medicine
Georgia Cancer Center, Augusta University
Dr. Jordan Ciuro MD is a clinical investigator and assistant professor of medicine at the Georgia Cancer Center specializing in genitourinary and breast oncology. She completed her Internal Medicine Residency as Chief Resident at Ascension Providence Hospital, Michigan State University. Here, she also completed her Oncology Fellowship as Chief Fellow. She is engaged in medical education, enjoys staying active in the community and believes in comprehensive and cutting-edge clinical care and trials.
Dr. Elisabeth Heath
Associate Center Director of Translational Sciences
Hartmann Endowed Chair for Prostate Cancer Research
Professor of Oncology and Medicine
Genitourinary Multidisciplinary Team Leader
Director, Prostate Cancer Research
Karmanos Cancer Institute
Wayne State University School of Medicine
Elisabeth I. Heath, M.D., F.A.C.P., serves as the Associate Center Director of Translational Sciences and leads the Genitourinary Oncology Multidisciplinary Team at the Karmanos Cancer Institute. She is the medical director of the Infusion Center and is director of prostate cancer research. She is an active clinical and scientific member of Karmanos and is professor of Oncology at Wayne State University School of Medicine.
Dr. Heath has a distinguished career as a prostate cancer researcher, serving as the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research. Her focus is in conducting clinical and translational research trials in genitourinary oncology with critical attention to the area of health disparity, particularly with regard to the poor accrual of minority patients to prostate cancer clinical trials. She is the principal investigator of the Michigan Prostate SPORE as well as for a Department of Defense grant in the nationally-recognized Prostate Clinical Trials Cancer Consortium.
Dr. Heath is a member of the Prostate Cancer Foundation Research Awards Review Committees and Department of Defense prostate and kidney cancer study section. She has served as president for the KCI Medical Executive Committee, has served as member of the Executive Committee of the Faculty Senate at Wayne State University School of Medicine, and is currently on the board of directors of the state-sponsored Michigan Cancer Consortium.
Dr. Heath was honored with the inaugural Michigan Cancer Consortium Champion Award for 2016. In addition, Dr. Heath was also the recipient of the National Cancer Institute Clinical Investigator Team Leadership Award in 2010. She has also been awarded the Wayne State University School of Medicine College Teaching Award in 2007, 2011, 2015 and holds the Top Doc designation in Hour Magazine from 2010-2021. Dr. Heath served for 10 years as the Faculty Advisor for the Gold Humanism Honor Society and has been the recipient of the Leonard Tow 2009 Humanism in Medicine Award. She was the recipient of the Wayne State University School of Medicine Physician’s Golden Heart Award in 2011. Dr. Heath is a dedicated clinician-scientist, researcher, and teacher at Wayne State University School of Medicine.
She earned her medical degree from Thomas Jefferson University in Philadelphia, PA, completed her internal medicine residency at Georgetown University Hospital, Washington, DC, and completed her medical oncology fellowship at Johns Hopkins School of Medicine, Baltimore, MD.
Dr. William Oh
Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute at Mount Sinai
Dr. William Oh is an expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers.
A leading investigator in the use of systemic treatments for prostate cancer, Dr. Oh has served as the principal investigator of multiple clinical trials in GU cancers. In addition, he developed large clinical databases and specimen repositories for GU cancers at both Harvard and Mount Sinai. He has authored more than 325 original articles, reviews and book chapters on topics relating to prostate, renal, bladder and testicular cancers. He has edited 3 books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS) and the American Urological Association (AUA), including the Guidelines Committee for Castration Resistant Prostate Cancer. He was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors and Super Doctors through 2022.
Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston and completed medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Oh was at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA for 14 years, where he served as Clinical Director of the Lank Center for Genitourinary Oncology and was founding Chair of the Data and Safety Monitoring Committee at the Dana-Farber/Harvard Cancer Center. Dr. Oh was also the Chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai for 11 years. He also served as Deputy Director of the Tisch Cancer Institute at Mount Sinai, which he helped to achieve NCI designation in 2015 and renewed in 2020.
Dr. Oliver Sartor
C.E. and Bernadine Laborde Professor of Cancer Research
Medical Director, Tulane Cancer Center
Associate Dean for Oncology
Tulane University School of Medicine
Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three phase III studies pivotal for FDA approval. He has lectured widely, and at last count has given invited lectures in 33 countries.
He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology) and is co-PI of the VISION trial, an international phase III study of Lu-177 PSMA in advanced prostate cancer.
Dr. Mary-Ellen Taplin
Chair, Executive Committee for Clinical Research
Director of Clinical Research, Lank Center for Genitourinary Oncology
Professor of Medicine, Harvard Medical School
Mary-Ellen Taplin, MD, is Professor of Medicine at Dana-Farber and Harvard Medical School. Dr. Taplin is the Principal Investigator for the Prostate Cancer Clinical Trial Consortium and a co-investigator on the Dana-Farber SPORE grant, Stand Up 2 Cancer, and Prostate Cancer Foundation Challenge grants and Principal Investigator of many transformative prostate cancer clinical trials.
Over the past 30 years, Dr. Taplin has been involved in clinical and translational prostate cancer research with a focus on secondary hormone therapy and molecular investigations of mechanisms of prostate cancer resistance involving adaptive androgen receptor alterations.
Dr. Taplin received her Doctor of Medicine in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology/hematology fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. After ten years on staff in medical oncology/hematology at the University of Massachusetts, in 2003 she joined Dana-Farber Cancer Institute. She is the recipient of the Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine (2010), the Claire W. and Richard P. Morse Research Award (2019) and a Fellow of the American Society of Clinical Oncology (2020).